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Abstract
Background: Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive breast cancer in which
approximately half the patients will progress to invasive cancer. Gaining a better understanding of DCIS progression
may reduce overtreatment of patients. Expression of the pro-inflammatory cytokine interleukin-6 increases with
pathological stage and grade, and is associated with poorer prognosis in breast cancer patients. Carcinoma
associated fibroblasts (CAFs), which are present in the stroma of DCIS patients are known to secrete
pro-inflammatory cytokines and promote tumor progression.
Methods: We hypothesized that IL-6 paracrine signaling between DCIS cells and CAFs mediates DCIS proliferation
and migration. To test this hypothesis, we utilized the mammary architecture and microenvironment engineering or
MAME model to study the interactions between human breast CAFs and human DCIS cells in 3D over time. We
specifically inhibited autocrine and paracrine IL-6 signaling to determine its contribution to early stage tumor
progression.
Results: Here, DCIS cells formed multicellular structures that exhibited increased proliferation and migration when
cultured with CAFs. Treatment with an IL-6 neutralizing antibody inhibited growth and migration of the
multicellular structures. Moreover, selective knockdown of IL-6 in CAFs, but not in DCIS cells, abrogated the
migratory phenotype.
Conclusion: Our results suggest that paracrine IL-6 signaling between preinvasive DCIS cells and stromal CAFs
represent an important factor in the initiation of DCIS progression to invasive breast carcinoma.
Keywords: Ductal carcinoma in situ (DCIS), Carcinoma-associated fibroblasts (CAFs), Interleukin-6 (IL-6),
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Background
Ductal carcinoma in situ (DCIS) of the breast is a pre-
invasive lesion and a risk factor for subsequent invasive
ductal carcinoma (IDC) [1]. DCIS represents about 20 %
of newly diagnosed breast cancers in the United States [2].
If left untreated, approximately half of DCIS tumors will
progress to IDC while half will remain indolent [3, 4].
Although there are many subtypes of DCIS, it is not cur-
rently possible to identify which will progress. This has led
to aggressive treatments, specifically radiation with either
lumpectomy or mastectomy [5].
Components of the tumor microenvironment are in-
creasingly implicated in the progression of many cancers.
Early morphological and physiological changes in breast
epithelium are minimal, and compounding factors such as
tumor-suppressive paracrine signaling from myoepithelial
cells [6] or the extracellular matrix [7] may hide early indi-
cators of ductal cell aberration. Such changes may include,
but are not limited to: gene expression modulation,
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epigenetic alterations, and loss of genomic stability in
both the epithelial and stromal compartments. In the
tumor microenvironment, carcinoma-associated fibro-
blasts (CAFs) represent a fibroblast population or mixture
of sub-populations that can promote tumor progression
[8–13]. Although this mechanism is not fully understood,
it is known that CAFs secrete numerous cytokines and
growth factors [14].
Interleukin 6 (IL-6) is a pro-inflammatory cytokine
shown to alter cell morphology, modulate cell migration
and the epithelial to mesenchymal transition [15–17].
Many of these processes occur upon IL-6 activation of
the transmembrane IL-6 receptor (IL-6R), which hetero-
dimerizes with the ubiquitously expressed cell surface
receptor glycoprotein 130 (gp130). Downstream activation
of the Janus kinase/signal transducers and activators of
transcription (JAK/STAT) pathway initiates IL-6 target
gene transcription [18, 19]. Alternatively, secreted IL-6
can bind to the soluble IL-6 receptor (sIL-6R), which then
binds gp130 at the cell surface and initiates intracellular
signaling. This form of IL-6 signaling has been coined
“IL-6 trans-signaling” (IL-6TS) [20]. IL-6 has been
linked to the upregulation of proteases such as cysteine
cathepsins and matrix metalloproteinases that are
known to play a role in cancer progression [21, 22].
The IL-6 signaling axis is commonly upregulated in in-
vasive cancers, suggesting that IL-6 may be an import-
ant mediator of events involved in tumor cell invasion
[23–25].
The effects of IL-6 signaling inhibitors on breast cancer
cell morphology and proliferation have been evaluated in
monotypic cultures. Two studies have shown that inhibit-
ing autocrine IL-6 signaling in either triple negative breast
cancer cell lines [26], or the ER-positive MCF7 cell line
[27] significantly inhibited cell growth. Additionally, Leslie
et al. show that knockdown of IL-6 in an invasive variant
of the MCF10A cells, MCF10A-H-RasV12, inhibited cell
migration in a transwell assay, and inhibited growth in a
xenograft mouse model [28]. Although these studies evalu-
ated paracrine signaling, cells were treated with exogenous
recombinant protein rather than co-culturing different cell
types. Therefore the authors were unable to evaluate in 3D
the dynamic cell:cell interactions between two separate hu-
man cell types or the cell:microenvironment interactions.
Our 3D mammary architecture and microenviron-
ment engineering (MAME) culture model mimics in
vivo architecture, providing a suitable setting to study
cell:cell interactions and, notably, physiologically rele-
vant cell:cell signaling over time. Additionally, 3D in
vitro cell culture models better represent in vivo tumor
drug response, which would facilitate efficacious ther-
apy development at the preclinical stage [29]. Here
we examine the role of IL-6 in progression of pre-
invasive breast DCIS to an invasive phenotype, and
show how co-culture of DCIS cells with CAFs changes
DCIS growth and invasive potential.
Methods
Cell lines
MCF10A human breast non-transformed epithelial
cells, MCF10.DCIS and SUM102 human breast DCIS
cells, and WS-12Ti human breast carcinoma-associated
fibroblasts were provided by Dr. Bonnie F. Sloane. All
primary fibroblasts were derived from human breast
tissue. CAF40T were derived from biopsy tissue diag-
nosed as invasive carcinoma. NAF98 were derived from
benign tissue. Both CAF40T and NAF98 fibroblast cell
lines were provided by Dr. Simon W. Hayward. These
fibroblasts were immortalized in Dr. Sloane’s lab and
are designated CAF40TKi and NAF98i, respectively.
The FB-NF, NAF-FB, and FB-CAF primary fibroblasts
were derived from patient biopsies diagnosed as: benign
(FB-NF, NAF-FB), or invasive carcinoma with accom-
panying DCIS (FB-CAF) and provided by Dr. Fariba
Behbod. The FB-NF fibroblasts were immortalized in
Dr. Sloane’s lab and designated FB-NF-i. The FB-CAF
and NAF-FB fibroblasts were not immortalized. All
patient derived cells were received de-identified and
therefore are exempt from IRB oversight.
Cell culture
In this study we utilized non-tumor forming MCF10A
human breast epithelial cells [30] and the human DCIS
cell lines MCF10.DCIS and SUM102, which were main-
tained as previously described [31]. See supplemental
methods for more detailed information (Additional file 1).
All 3D MAME cultures were performed using Cultrex
(3433-005-01, Trevigen, Gaithersburg, MD) similar to
previously described [32]. Briefly, cell culture dishes were
coated with 100 % Cultrex. Cells were added on top of
solidified Cultrex and allowed to adhere for 30–45 min
before being overlaid with 2 % Cultrex in phenol red-free
DMEM F12 media containing 2.5 % fetal bovine serum
(Additional file 2: Figure S1). In co-culture experiments,
fibroblasts were added first and allowed to adhere before
adding tumor cells. Once tumor cells had adhered to the
matrix, an overlay of 2 % Cultrex was added. Media were
changed every 4 days.
Measurement of multicellular structures
Differential interference contrast (DIC) images of three
random fields at 20X magnification were used to meas-
ure multicellular structures. Three individuals of whom
two were study-blinded measured the diameter and
perimeter of structures and the number and length of
interconnections between structures. All three data sets
were used in the quantification. This analysis was per-
formed using Zen imaging software (Zeiss, Thornwood,
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NY). Volume measurements were obtained using 3D fluor-
escent images and quantified using Volocity software
(Perkin-Elmer, Waltham, Mass).
Gene expression
RNA was isolated from cells grown in either 2D mono-
layer or 3D MAME cultures. For 2D culture, cells were
washed in phosphate buffered saline and harvested using
0.5 % Trypsin/EDTA (Life Technologies, Foster City, CA)
and pelleted. The cell pellets were resuspended in TRIzol®
Reagent (Life Technologies, Foster City, CA) for RNA ex-
traction. All qRT-PCR reactions were performed using
Taqman Assays (Life Technologies, Foster City, CA).
See supplemental list of Taqman Assays (Additional
file 3: Table S1).
ELISA
ELISA kits (human IL6R-ab46029, human IL6-ab46044,
and human GAPDH-ab119627) were purchased from
Abcam® (San Francisco, CA). Aliquots of lysates were col-
lected for ELISA assays and measurement of total DNA.
Immunohistochemistry
A breast tissue microarray (BR8011) was purchased from
US Biomax® (Rockville, MD). Dr. Fariba Behbod pro-
vided patient tissue microarrays, and biopsy sections
were purchased from ProSci Incorporated (cat # 10–010
and 10–003, Poway, CA). The thickness of all tissue sec-
tions immunostained were 10-microns.
Immunofluorescence
Nuclei were labeled with Hoechst (33342, Thermo Scien-
tific) or EDU (Life Technologies, Foster City, CA). Poly-
clonal antibodies to human IL-6 (AF-206-NA, R&D
Systems, Minneapolis, MN) were used at a concentration
of 1 μg/ml. Mono-specific antibodies to human cathepsin
B have been previously isolated and characterized [33].
Cathepsin B immunostaining was performed as previously
described with the exception that 1 % Tween 20 replaced
the 0.01 % saponin [34]. For some studies, CAF40TKi
were pre-labeled, prior to seeding in MAME co-cultures,
utilizing CellTrace CFSE (carboxyfluorescein diacetate
succinimidyl ester; Life Technologies, Foster City, CA) ac-
cording to the manufacturer’s protocol.
Drug treatments
For treatment of MAME cultures with IL-6 nAb (R&D
Systems, AF-206-NA), we added 1 μg/ml of IL-6 nAb in
the 2 % Cultrex overlay to 3D cultures on the first day
of culture and refreshed with IL-6 nAb and 2 % overlay
every 4 days. The antibody concentration was selected
based on preliminary studies in which we determined
the lowest concentration needed to inhibit growth of
tumor structures. Oxymatrine (Sigma, St. Louis, MO) at
1-mg/ml (3.7 mM) was added 24 hours after cell seeding
and was replaced with fresh drug every 4 days. The oxy-
matrine concentration was determined empirically based
on the concentration at which proliferation was inhibited
to 50 % of control. The protease inhibitors CA074Me and
E64d (Sigma, St. Louis, MO) were used at a concentration
of 10 μM [35].
Live cell proteolysis assay
Dye-quenched collagen IV (DQ-collagen IV, Life Tech-
nologies, Foster City, CA) was used admixed in Cultrex
as previously described [32]. MAME cultures in optical
glass bottom cell culture dishes were imaged live for a
period of 10 to 60 min under 5 % CO2 at 37 °C.
Confocal microscopy
Confocal microscopy was performed on either a Zeiss
LSM 510 or LSM 780 upright confocal microscope (Zeiss,
Thornwood, NY). All cell cultures used for imaging were
seeded on 40 mm optical glass bottom culture dishes at a
density of 45 cells/mm2 (~5000 cells/dish).
Statistics
Data were statistically analyzed using Student’s t-test
on GraphPad Prism 6.0 (GraphPad Software Inc., La
Jolla, CA).
Ethics statement
All human subject materials and experiments in this
study have been reviewed by the Wayne State University
Institutional Review Board and deemed exempt accord-
ing to the definition codified in the common rule at 45
CFR 46.102(d)(f ).
Results
Human breast DCIS cells express pro-inflammatory
cytokines
Increased levels of pro-inflammatory cytokines, includ-
ing IL-6, in tumors and serum of breast cancer patients
correlate with poor prognosis [26, 36–38]. Immunohis-
tochemistry on breast tissue from female patients, age
30 to 81 with an average age of 49.5, confirmed IL-6
protein expression in 65 % of patient samples diagnosed
with DCIS (Fig. 1a and b, cf. 1c and d).
We utilized a 3D MAME culture model (Additional
file 2: Figure S1), to study the role of IL-6 signaling be-
tween human breast DCIS cells and human breast CAFs.
The MAME model allows for co-culture of multiple cell
types in the context of a three dimensional microenvir-
onment. Our model is advantageous over commercially
available 3D platforms as it can be utilized for live cell
microscopy, and imaging live cell functional assays (such
as proteolysis) [32]. MAME cultures are tractable and
can be altered to grow multiple cell types at various
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ratios or at various relative positions within the matrix.
Additionally, the reduced density overlay allows for real-
time collection and analysis of cytokine secretion without
disrupting the longitudinal growth of the culture.
Here we examined the expression of IL-6 and the
associated pro-inflammatory genes interleukin 1β (IL1β)
and nuclear factor kappa light chain enhancer of activated
B cells 1 (NFκB1) in human breast MCF10.DCIS and
SUM102 cell lines. Our data show higher IL-6 mRNA
levels in both MCF10.DCIS and SUM102 cell lines, as
compared to the MCF10A breast epithelial cell line
(Fig. 1e). Levels of IL-6 protein in lysates of the three cell
lines were below the level of detection. When we mea-
sured secreted IL-6 in conditioned media from
MCF10.DCIS or SUM102 cultures, we found that
both DCIS cell lines secreted 10 to 30-fold more IL-6
than the MCF10A cells (Fig. 1f ).
Blocking IL-6 autocrine signaling inhibits MCF10.DCIS
growth
To test whether blocking IL-6 autocrine signaling af-
fected DCIS cell growth, we treated MCF10.DCIS
MAME cultures for 8 days with either an IL-6 neutral-
izing antibody (nAb) or an equivalent concentration of
Fig. 1 Breast DCIS cells overexpress proinflammatory markers. Representative images of immunohistochemistry targeting IL-6 protein in normal
breast tissue (a), and breast DCIS (b) (N = 61). c and d Hematoxylin staining of serial sections from tissue shown in panel A and B. All images are
20X magnification. Scale bar equals 100 μm. e Evaluation of IL-6 gene expression in DCIS cells via qRT-PCR; the isogenic MCF10.DCIS cells and the
non-isogenic SUM102 cell line were analyzed against the non-transformed MCF10A cell line (N = 3). f Secretion of IL-6 protein from DCIS cell lines
and non-transformed MCF10A cells as determined by ELISA. *P < 0.05, Student’s t-test; mean ± SD
Osuala et al. BMC Cancer  (2015) 15:584 Page 4 of 14
a species and isotype matched antibody (Fig. 2). IL-6
nAb treatment resulted in a reduction in diameter of
the multicellular 3D structures (Fig. 2b, cf. 2a, quanti-
fied in 2d). This was reversible as replacement of media
on day 8, with media lacking IL-6 nAb, resulted in a signifi-
cant increase in diameter of the MCF10.DCIS structures
after an additional 48 h (Fig. 2c, cf. 2b, quantified in 2d).
To determine the effects of IL-6 nAb on MCF10.DCIS
structures, we examined the expression of a panel of can-
didate genes that have been associated with tumor growth
and invasion [39–43]. The expression of IL-6 was upregu-
lated 2-fold in the treated cultures. The expression of
TWIST1, vimentin, and Fibroblast Growth Factor 2 was
downregulated greater than 2-fold, while minimal changes
were observed in the expression of E-cadherin, N-cad-
herin, and NFκB1 (Fig. 2e). To test whether pharmaco-
logical suppression of IL-6 could reproduce IL-6 nAb
mediated growth inhibition, we treated cells with oxy-
matrine, a naturally occurring inhibitor of IL-6 gene ex-
pression. Oxymatrine has been shown to prevent nuclear
translocation of NFκB-p65 thereby inhibiting transcrip-
tional activation of its target genes, which include IL-6 [44].
Oxymatrine treatment was able to replicate the growth in-
hibitory effects observed with IL-6 nAb (Additional file 4:
Figure S2B, cf. S2A, quantified in S2C). Neither oxyma-
trine nor IL-6 nAb treatment resulted in marked cell
death as cytotoxicity assays showed no difference in
cell viability after 48-hour drug treatment (Additional
file 4: Figure S2D).
Carcinoma-associated fibroblasts express IL-6 and promote
DCIS cell proliferation and motility
CAFs represent a population or group of populations
of stromal cells that can promote tumor cell growth
[14, 45–47]. The mechanism of supported tumor
growth is likely through stromal-epithelial paracrine
signaling. Therefore, we next evaluated human breast
CAFs to determine their contribution of IL-6 in the
tumor microenvironment. Additionally, we examined
the role that CAFs play in MCF10.DCIS cell prolifera-
tion and motility in the 3D MAME model.
We examined the expression of IL-6 mRNA in normal
human fibroblasts and CAFs grown in 3D. Here we
found that CAFs exhibited elevated expression of IL-6
mRNA compared to normal fibroblasts (Fig. 3a). Protein
levels of IL-6 in FB-NF-i normal fibroblast lysates were
near the lower limit of detection and undetectable in
NAF-FB or NAF98i lysates. IL-6 levels in CAF40TKi
Fig. 2 IL-6 neutralizing antibody (nAb) inhibits growth of MCF10.DCIS structures. Representative contiguous 16-tiled DIC images of MCF10.DCIS
cells grown in MAME cultures for 8 days. MAME culture of MCF10.DCIS cells treated with an isotype-matched antibody against IgG (control)
(8 days) (a), or 1 μg /ml IL-6 nAb (b) (8 days). MCF10.DCIS cells treated with IL-6 nAb followed by a 48 h treatment-free recovery period prior to
imaging on day 10 (c). N = 3, Scale bars, 200 μm. d Diameter of MCF10.DCIS structures in the presence of control antibody, IL-6 nAb, or 48 h
recovery from IL-6 nAb. N = 20-40 measurements /tiled DIC image (N = 3). ****P≤ 0.0001, **P ≤ 0.01. e Evaluation of gene expression of invasive
tumor cell markers in MAME cultures treated with IL-6 nAb (N = 3). Fold difference as compared to control cultures. Dashed line indicates 2-fold
threshold. Student’s t-test; mean ± SD
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lysates were significantly higher than in FB-NF-i lysates
(Fig. 3b). Levels of IL-6 in CAF-conditioned media were
higher than in normal fibroblast-conditioned media
(Fig. 3c).
We next co-cultured MCF10.DCIS cells with CAFs in
3D, at a seeding ratio of five tumor cells to one CAF [32],
to evaluate the effect of CAF-secreted cytokines on DCIS
cell proliferation and related changes in morphology of
multicellular structures. We found that in MCF10.DCIS:C
AF40TKi co-cultures there was an increase in the average
diameter and volume of the multicellular structures and
a prominent formation of branch-like interconnections
between the structures (Fig. 3e, cf. 3d, quantified in
Additional file 5: Figure S3A). Fluorescent imaging of
MCF10.DCIS:CAF40TKi 3D co-cultures revealed that the
branch-like multicellular connections between structures
were primarily composed of tumor cells, yet contained
some CAFs (Additional file 5: Figure S3B and Additional
file 6: Video S1).
We also observed that CAFs induced an increased rate
of proliferation in MCF10.DCIS cells. Using a thymidine
analog to evaluate the rate of DNA synthesis, we observed
that co-cultures had a consistently higher rate of DNA
synthesis than CAFs alone or DCIS cells alone (Additional
file 7: Figure S4A-D). CAF and DCIS co-culture using a
slower growing DCIS cell line, i.e., SUM102, also resulted
in changes in multicellular structure formation. We ob-
served the presence of multiple invasive processes in
SUM102:CAF co-cultures that were completely absent in
cultures of the SUM102 cells alone (Additional file 8: Figure
S5C and D, arrow, cf. S5A and B).
DCIS cells migrate with CAFs at the invasive front
CAFs express and secrete a number of proteases, which
enhance their ability to migrate and remodel extracellu-
lar matrices [48–51]. In CAF:MCF10.DCIS co-cultures,
we evaluated cell:cell interactions and motility. Here we
found that MCF10.DCIS spheroids formed attachments
to CAFs and remained associated with them throughout
an 8-day culture. On day 1 (24 h after seeding) of a co-
culture we observed many single DCIS cells and a few
CSFE labeled CAFs (Fig. 4a). After 3 days in culture
DCIS cells had formed small spheroids that were in con-
tact with one or more CAFs (Fig. 4b). On day 5 we
Fig. 3 Carcinoma-associated fibroblasts (CAFs) have high expression of IL-6 and promote MCF10.DCIS growth. a Expression of IL-6 mRNA in three
CAF cell lines (FB-CAF, CAF40TKi, WS12Ti) and three normal fibroblast cell lines (NAF-FB, FB-NF-Ki, NAF-98i) (Fold difference relative to MCF-10A
non-transformed epithelial cells) (N = 3). b-c IL-6 protein concentration in cell lysates and media as determined by ELISA (N = 3-5) (Also see
Additional file 4: Figure S2E). ****P≤ 0.0001, Student’s t-test; mean ± SD d Representative contiguous tiled DIC image of MCF10.DCIS cells grown
in MAME culture for 8 days. e Co-culture of MCF10.DCIS cells with CAF40TKi fibroblasts for 8 days. Dashed red line outlines multicellular structures
formed in co-culture. Arrows identify interconnecting structures. Scale bars, 200 μm
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observed CAFs at the invasive edges of DCIS tumor
spheroids. A representative image shows a CAF
(Fig. 4c, arrow) in contact with a DCIS spheroid. A
time-lapse video shows the CAF leading the DCIS
spheroid (Additional file 9: Video S2). High magnifica-
tion imaging shows heterocellular contact between a
tumor structure and a single CAF (Additional file 10:
Figure S6). We did not observe these invasive charac-
teristics in DCIS cell grown alone, as the tumor struc-
tures tended to roll in the extracellular matrix
(Additional file 11: Video S3). By day 7 CAFs were seen
at the invasive edge of most tumor structures (Fig. 4d).
Using confocal microscopy we examined the 3D spatial
organization of the DCIS cells in relation to CAFs. A top
view of a 3D reconstruction shows an MCF10.DCIS struc-
ture (only nuclei labeled) branching out toward CFSE la-
beled CAFs (pseudo-colored white) (Fig. 4e, Additional
file 12: Video S4). The core of this structure (dashed cir-
cle) formed shortly after seeding and grew in size before
the two branching outgrowths formed. These outgrowths
are reminiscent of the “strand” multicellular migration
pattern previously described [52]. A side view of the same
structure shows that DCIS cells migrated downward from
the core structure toward the CAFs (Fig. 4f).
Fig. 4 DCIS cells migrate preferentially towards CAFs in MAME co-culture. Representative DIC/fluorescent overlay image of MCF10.DCIS cells (unlabeled)
with CAF40TKi fibroblasts (green) at day 1 (a) and 3 (b). Scale bar, 50 μm. Orange arrow indicates migration direction (ref. Additional file 9: Video S2).
c Video snapshot of live cell imaging between days 3 and 4 shows a tumor spheroid attached to a single fibroblast (Arrow; ref. Additional file 9: Video S2).
d At day 7, tumor cells have proliferated and formed protruding structures, which are connected to fibroblasts. Scale bar, 100 μm. e Representative 3D
reconstructed image showing aerial view (e) and side view (f) of MAME MCF10.DCIS:CAF40TKi co-culture (ref. Additional file 11: Video S3). A primary
MCF10.DCIS spheroid (dashed white circle) can be seen with lateral protrusions towards fibroblasts (CFSE-labeled and pseudo-colored white). Nuclei are
stained with DAPI (purple). 1 Unit = 45 μm
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IL-6 protein expression in these co-cultures was
detected using immunofluorescent staining (Additional
file 13: Figure S7). A CFSE-labeled CAF showed high
expression of IL-6, whereas the leading edge of the
DCIS multicellular structure showed a gradient of IL-6
that was strongest near the attachment to the CAF
(Additional file 13: Figure S7A, arrow). We also showed
that MCF10.DCIS cells that do not migrate to serum-
free media (Additional file 13: Figure S7D) migrated to-
ward CAF-conditioned serum-free media (Additional
file 13: Figure S7E, S7F).
CAFs and MCF10.DCIS cells utilize cathepsin B to degrade
matrix
IL-6 has previously been shown to upregulate cathepsin B
[21], a protease associated with breast cancer progression.
Therefore, we examined the expression and localization of
cathepsin B in relation to active proteolysis in our 3D
MAME co-cultures. Our active proteolysis assays were
performed during live cell imaging [33]. Fluorescent im-
aging of live cells in MAME co-culture revealed regions of
proteolytic activity (green) around several multicellular
structures (Fig. 5a). The cells were then fixed for cathepsin
B immunofluorescent staining. Visualizing the same struc-
tures revealed cathepsin B expression at the interface be-
tween the multicellular structures and the matrix (Fig. 5b).
Fluorescent overlay shows co-localization between DQ-
collagen IV degradation and areas with high cathepsin B
expression (Fig. 5c); however, matrix degradation also oc-
curred in areas that did not stain for cathepsin B (arrow).
Upon visualization using light microscopy, the cells in
these areas had morphological features consistent with
CAFs, which would be consistent with current knowledge
of fibroblast migration and their secretion of many prote-
ases in addition to cathepsin B [53, 54].
We then used protease inhibitors to determine the con-
tribution of all cysteine proteases and/or cathepsin B and
L, to the overall proteolysis in the MAME culture. We
treated cultures with E64d, a cell permeable pan-cysteine
protease inhibitor, and found a 30 – 40 % reduction of
matrix degradation (Fig. 5d). We also treated cultures with
the cell permeable cathepsin B/L inhibitor, CA074Me, and
found a 60 – 70 % reduction in matrix degradation
(Fig. 5e). CA074Me has previously been shown to be a
more efficacious inhibitor against cathepsins B and L than
is E64d [35, 55]. We did not observe complete inhibition
of proteolysis with the cysteine protease inhibitors, a find-
ing in accord with previous findings that DCIS cells and
CAFs secrete many non-cysteine proteases [31, 56, 57].
Blocking IL-6 inhibits CAF-stimulated effects on human
breast DCIS cells
We have shown that CAFs promote the proliferation and
migration of human breast DCIS cells. To determine
Fig. 5 MAME co-cultures of MCF10.DCIS:CAF40TKi show expression of the cysteine protease cathepsin B at sites of proteolysis of matrix.
a Representative confocal image obtained from the equatorial plane, showing live cell proteolysis via degraded DQ-collagen IV (dDQ-Col.IV).
Fluorescent signal intensity correlates with degree of proteolysis. b Immunofluorescent staining for cathepsin B (red) in the equatorial plane.
c Fluorescent overlay of dDQ-Col.IV (green) and cathepsin B immunostaining (red). Scale bar, 200 μm. Quantification of dDQ-Col.IV fluorescent
intensity in MAME co-cultures treated with cell permeable inhibitors E64d (pan-cysteine protease inhibitor) (d) or the cathepsin B selective
inhibitor CA074-Me (e). *P < 0.05, Student’s t-test; mean ± SD
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whether CAF-stimulated migration and interaction with
MCF10.DCIS cells could be inhibited by blocking IL-6, we
co-cultured MCF10.DCIS cells with two human breast
carcinoma-associated fibroblast lines WS-12Ti or CAF40
TKi, in the presence of IL-6 nAb or an isotype control
antibody. IL-6 nAb reduced the size of MCF10.DCIS:CAF
multicellular structures when grown with either CAF cell
line (Fig. 6a-e). Multicellular structure volume measure-
ments confirmed a significant reduction when treated with
IL-6 nAb (Fig. 6f-h).
To confirm the role of IL-6 as a key player in the for-
mation of the multicellular structure interconnections,
we utilized shRNA targeting IL-6 expression. In CAF40T
Ki and MCF10.DCIS cells, we achieved greater than
50 % reduction in secreted IL-6 (Additional file 14:
Figure S8A). When we co-cultured CAF40TKi-shRNA
control fibroblasts with MCF10.DCIS cells, we saw a
phenotype similar to non-shRNA transduced cultures
(Additional file 14: Figure S8B, cf. 3E). Knocking down
CAF40TKi IL-6 expression in co-culture resulted in the
formation of multicellular structures with uniform
borders and few invasive processes (Additional file 14:
Figure S8C). Co-culture with non-shRNA transduced
CAF40TKi fibroblasts and shRNA-IL-6 transduced
MCF10.DCIS cells showed greater MCF10.DCIS:CAF
40TKi interaction and multicellular structure branching
(Additional file 14: Figure S8D).
IL-6 signaling is propagated through either direct cell
membrane receptor signaling or soluble receptor trans-
signaling (TS). In the DCIS cell lines, we found that IL-
6R expression was low and sometimes undetectable by
qRT-PCR. Additionally, we detected very low levels of
sIL-6R secreted from MCF10.DCIS cells and none from
SUM102 cells. In contrast, CAFs had a higher level of
IL-6R gene expression and high secretion of sIL-6R as
verified by ELISA. These findings suggest that IL-6TS
is a likely mechanism of IL-6 action in these DCIS cells
[58] (Additional file 15: Figure S9).
Discussion
A number of factors produced by CAFs have been shown
to be involved in promoting malignant transformation in
epithelial cells, these include TGFß [59–61] and CXCL12
(SDF-1) [59, 61, 62]. These factors are involved in eliciting
a range of responses that are context-dependent and that
benefit the tumor in various ways. The present study
Fig. 6 IL-6 nAb inhibits CAF-stimulated MCF10.DCIS structure growth and results in altered morphology. Contiguous 16-tile DIC image of CAFs:
WS12Ti (A, B) or CAF40TKi (c, d) co-cultured with MCF10.DCIS cells for 8 days in the presence of isotype matched anti-IgG (a, c) or 1 μg /ml IL-6
nAb (b, d). e Perimeter measurements from DCIS structures in MAME culture in the presence of anti-IgG or IL-6 nAb (N = 100-140 measurements
from 6 contiguous tiled DIC images (N = 3). Fluorescent tiled images of CAF40TKi fibroblasts (unlabeled) cultured with MCF10.DCIS-RFP cells in
the presence of anti-IgG (f) or 1 μg /ml IL-6 nAb (g). h Quantification of total volume of DCIS-RFP structures in co-culture with CAF40TKi
fibroblasts (ratio-paired t-test, N = 3). ***P≤ 0.001, **P ≤ 0.01; Student’s t-test; mean ± SD
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describes a novel addition to these known interactions and
a new mechanism by which CAF can influence tumor
progression. There is a direct correlation between
serum IL-6 levels and poor prognosis in breast cancer
patients [36, 63–65]. Studies have shown that CAFs
[66], and various immune/inflammatory cells secrete
pro-inflammatory cytokines including IL-6 and contrib-
ute to tumorigenicity [67–73].
In the current study, we show that IL-6 expression can
be found in both the tumor and stromal compartments.
In our IHC data we found approximately 65 % of patient
samples had positive IL-6 staining; however, when we
examined IL-6 expression in our DCIS tumor cell lines,
we found the expression to be near the lower threshold
of our assay. This discrepancy may be due to differences
in gene expression between tissue and cells [74], differ-
ences in IL-6 expression with tumor grade/invasiveness
[65], degree of “stemness” in cell lines vs. tissue [75], and
differences between the assays and/or sample collection.
We next examined the interaction between human
breast DCIS epithelial cells and human breast CAFs in
the context of an in vitro 3D microenvironment. We hy-
pothesized that CAFs promoted the migration of breast
DCIS cells via paracrine signaling within the tumor
microenvironment. Here we observed that DCIS cells
migrated towards CAFs and upon attachment to CAFs,
DCIS cells remained attached and migrated through the
matrix following the lead of the CAFs. Similar findings
of fibroblast-led migration have been reported for co-
cultures of invasive squamous carcinoma cells and CAFs
[76]. It is also likely that CAFs migrated to DCIS cells,
as some fibroblasts moved more easily and quickly
through the matrix as seen in time-lapse videos; there-
fore it is possible that some fibroblasts migrated to and
attached to DCIS cells thereupon leading migration of
the DCIS cells.
An increase in DCIS cell proliferation and a change in
multicellular structure morphology was observed in all of
our co-culture experiments. DCIS multicellular structures
showed invasive characteristics, having lost their uniform
circular structure and had developed single or multiple
protruding edges. An underlying mechanism for DCIS:CA
F interaction, enhanced tumor cell proliferation, and mi-
gration was IL-6 signaling in the tumor microenviron-
ment. We [31] as well as Sung et al. [77] have shown in
3D co-culture systems that paracrine HGF and its receptor
cMet can drive the invasive potential of the MCF10.DCIS
cells. We confirmed this in xenografts formed by orthoto-
pic implantation of HGF-secreting fibroblasts and MCF10
.DCIS cells in SCID mice [31]. HGF and IL-6 have been
shown to cooperatively enhance lung cancer cell invasion
by upregulation of their corresponding cell surface recep-
tors [78]. Also of interest is the stem cell-like properties of
the proliferating DCIS cell population as Krishnamurthy
et al. have shown that endothelial IL-6 enhances self-
renewal of cancer stem-like cells. Whether or not this is
the case for CAF IL-6 in regard to proliferation of DCIS
cells has yet to be determined [79].
Treatment of DCIS:CAF co-cultures with an IL-6 nAb
abrogated the proliferation and migratory phenotype
acquired by DCIS cells. This phenotype was primarily pro-
duced by the inhibition of CAF secreted IL-6 as shRNA
knockdown of IL-6 in CAFs, but not in DCIS cells was
able to replicate the phenotype. We also showed that
MCF10.DCIS cells treated with IL-6 nAb had a down
regulation of genes associated with EMT. A recent study
suggests that tumor cell EMT is mediated through factors
secreted from CAFs and that selective inhibition of TGFβ1
is sufficient to reverse EMT associated gene expression
[80]. Other studies show cross talk between IL-6 and
TGFβ signaling consistent with IL-6 and TGFβ both act-
ing as drivers of EMT [81].
A Federal Drug Administration (FDA) approved hu-
manized anti-IL-6R antibody, tocilizumab (Actemra), has
shown promise in the treatment of inflammatory diseases
particularly rheumatoid arthritis, Crohn’s disease, and
Castleman’s disease. A major caveat of Actemra is that
serum IL-6 levels are increased in patients after drug
administration [82]. Since breast cancer patients with
elevated serum IL-6 have poorer prognosis, Actemra
may not be a practical therapy in these patients, how-
ever alternative approaches to reduce IL-6 signaling
may prove efficacious.
Siltuximab, a monoclonal antibody against IL-6, is in
clinical trials for therapies including; combinatorial
treatment of metastatic renal cell carcinoma, multiple
myeloma, and prostate cancer [83–86]. The FDA re-
cently approved siltuximab for the treatment of multi-
centric Castleman’s disease [87]. Studies have shown
that siltuximab significantly inhibits the growth of non-
small-cell lung cancer in primary xenografts [88], and
ovarian cancer cell xenografts [89]. Therapeutic use of
siltuximab for the treatment of breast cancer has not
been fully evaluated, although preliminary studies with
the estrogen receptor alpha positive MCF-7 breast can-
cer cell line suggests potential efficacy [90].
A limitation of the current study is that we did not
have complete histories or demographic data to perform
correlation studies to determine how IL-6 expression in
DCIS relates to tumor prognosis. Another limitation is
there is a limited number of commercially available
DCIS cell lines. Here we used two cell lines that are
commercially available. A third DCIS cell line that is
commercially available is the SUM-225 DCIS cell line;
however, this line comes from a metastatic recurrence so
we chose not to use it. Another limitation is that our
study only followed the progression and interaction of
DCIS cells with CAFs, but not inflammatory cells
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associated with breast tumors. Additionally, we are in-
vestigating the probability of increasing the number of
cell types grown together in our 3D MAME culture, for
example: macrophages, adipocytes and lymphocytes.
Conclusion
In conclusion, we have shown that IL-6 paracrine signal-
ing between DCIS cells and CAFs is a key mediator of
early stage breast cancer cell proliferation and migration.
Furthermore, IL-6 from CAFs facilitated the transition of
DCIS cells from preinvasive to an invasive phenotype.
This study highlights the necessity to explore paracrine
signaling within the context of the tumor microenviron-
ment and components therein.
Additional files
Additional file 1: Supplemental Materials and Methods.
(DOCX 126 kb)
Additional file 2: Figure S1. Schematic diagram of 3D mammary
architecture and microenvironment engineering (MAME) model. In this
mixed cell type model, glass bottom dishes or coverslips are coated with
100 % Cultrex and placed in a 37° 5 % CO2 incubator for 20 min. This
allows the Cultrex to solidify. Here we added fibroblasts to the solidified
matrix and allowed them to attach for a period of 30–45 min. After
fibroblasts have adhered to the matrix tumor cells are added. An
additional 30–45 min is required to allow tumor cells to adhere. After
tumor cells have adhered, an overlay of 2 % Cultrex diluted with cell
culture media containing 2.5 % fetal bovine serum is added. (TIFF 125 kb)
Additional file 3: Table S1. Taqman Gene Expression Assays. Taqman
Assays (primers) were selected for the human gene targets. Each Taqman
Assay was selected based on suppliers “best coverage” criteria.
(TIFF 83 kb)
Additional file 4: Figure S2. Oxymatrine treatment. (A-B) MCF10.DCIS
cells were grown in the presence of DMSO (A) or 1 mg/ml oxymatrine
(B). Oxymatrine or DMSO was added 1 day after initial seeding. Scale bar,
200 μm. MCF10.DCIS cells grown in DMSO form large structures similar to
untreated cultures (cf. Fig. 2a). (C) Measurement of structure diameters in
three tiled images from three independent experiments. (D) Cell viability
was evaluated using an ATP-based luminescence assay 24 h after drug
treatment. Arbitrary units (A.U.). **P < 0.01, not significant (NS). Student’s
t-test; mean ± SD. (TIFF 141 kb)
Additional file 5: Figure S3. Co-culture of MCF10.DCIS cells and CAFs
increased MCF10.DCIS structure size and length of interconnections
between multicellular structures. (A) Measurements taken from contiguous
16-tiled image of MCF10.DCIS cells alone (open box) or co-cultured (shaded
box) with CAF40TKi fibroblasts showed a significant increase in the diameter
of multicellular structures and length of interconnections between structures
(N = 15). (B) Interconnections between multicellular structures were
composed primarily of MCF10.DCIS cells. Reconstructed confocal image
of MCF10.DCIS-RFP cells (red) grown in MAME co-culture with
CAF40TKi-CFSE cells (green) for 8 days. CAF40TKi CFSE-labeled
fibroblasts clustered near invasive edges (arrows). 20X magnification.
***P < 0.001. (TIFF 150 kb)
Additional file 6: Video S1. 360° views of a branching nodular
structure consisting of MCF10.DCIS cells (red) and CAF40TKi fibroblasts
(green). Image obtained on a Zeiss LSM 780 and converted to a movie
file using Volocity® software. (MOV 1 mb)
Additional file 7: Figure S4. MCF10.DCIS: CAF40TKi MAME co-culture
increased cell proliferation. (A) Lack of 5-Ethynyl-2´-deoxyuridine (EDU)
thymidine analog incorporation in CAF40TKi fibroblasts grown for 5 days.
Arrows point out fibroblasts scattered throughout the culture. Scale bar,
200 μm. (B) Incorporation of EDU in MCF10.DCIS cells grown for 5 days.
(C) Incorporation of EDU in a representative structure from a MCF10.DCIS:
CAF40TKi co-culture. Note that similar sized structures were chosen to
compare levels of EDU incorporation in a 24-h period. Scale bars, 100 μm.
(D) DNA was extracted from MAME cultures to quantify EDU concentration.
Data shows a significantly higher concentration of EDU incorporation in
DNA of co-culture as compared to monotypic cultures. ***P < 0.001, ****P
< 0.0001, Student’s t-test; mean ± SD. (TIFF 344 kb)
Additional file 8: Figure S5. Carcinoma-associated fibroblasts enhance
invasive growth of SUM102 cells in MAME co-culture. (A) Representative
contiguous tile image of SUM102 cells grown in MAME culture for 8 days
(N = 3). (B) Single field from panel A shows spheroidal SUM102 structures.
(C) Representative MAME co-culture of SUM102 and CAF40TKi cells
(N = 3). (D) Single field from panel C shows SUM102 cells having many
invasive outgrowths (arrow). Scale bar, 50 μm (B and D), 200 μm
(A and C). (TIFF 963 kb)
Additional file 9: Video S2. Video clip shows MAME co-culture of
unlabeled MCF10.DCIS cells with CAF40TKi fibroblasts. Day 5 of an 8-day
culture. Computer curser is used to outline a CAF (single cell) and the
tumor spheroids (5 identified in video). Tumor spheroids have a
characteristic rotating motion that is noticed immediately. CAFs, only two
in the field of view, tend to migrate freely in the 3D matrix. The CAFs
extend fingerlike cytoplasmic projections up to 100 μm in length.
Time-lapse video captured using a Perkin Elmer UltraVIEW ERS confocal
microscope. (MOV 28 mb)
Additional file 10: Figure S6. MCF10.DCIS multicellular structures form
heterocellular contacts with CAFs. (A) An 8-day 3D MAME co-culture of
MCF10.DCIS cells and CAF40TKi fibroblasts show a CFSE labeled fibroblast
at the invasive edge of a multicellular DCIS structure. Scale bar equals 50
μm. (B) High magnification zoom reveals the contact region as a dense
demarcation between tumor and fibroblast. Color removed to enhance
visualization of heterocellular contact. (TIFF 766 kb)
Additional file 11: Video S3. Video clip of MCF10.DCIS cells on day 5
of an 8-day 3D MAME culture. The tumor cells have formed a spheroid
and display a rotational motion in the extracellular matrix. Time-lapse
video captured using a Perkin Elmer UltraVIEW ERS confocal microscope.
(MOV 2241 kb)
Additional file 12: Video S4. Video clip shows the transition through
optical slices of a MCF10.DCIS structure in co-culture with CAF40TKi
fibroblasts (Full 3D image shown in Fig. 4e and f). Cultures were fixed
and immunostained for IL-6 (red), with DAPI labeled nuclei. MCF10.DCIS
cells formed large nodular-like structures that branched out towards
CFSE-labeled CAFs (pseudo-colored white). Images were obtained on a
Zeiss LSM 780 and converted to a movie file using Volocity® software.
(MOV 1 mb)
Additional file 13: Figure S7. CAF-conditioned medium induces
MCF10.DCIS cell migration. (A) A representative CAF40TKi fibroblast
expresses IL-6 (red) as it leads an MCF10.DCIS structure during collective
migration (collective migration is inferred based on observations from
time-lapse microscopy, see Movie 2). An MCF10.DCIS structure (arrow)
shows a gradient of IL-6 expression (red) that is most intense near a
cell:cell attachment with a CAF40TKi fibroblast. (B) DIC/fluorescent overlay
image identifies the single leading cell as a CFSE-labeled CAF40TKi
fibroblast (green). MCF10.DCIS cells are unlabeled. (C) Fluorescence only
overlay of panels A and B. Scale bar, 20 μm. (D) A migration assay
membrane showed that MCF10.DCIS cells do not migrate through
transwell membrane pores to serum-free media. (E) MCF10.DCIS cell
migrate through the transwell membrane pores to CAF40TKi conditioned
serum-free media. (F) Quantification of visible cells that have migrated
through transwell membrane filter after 24 h. (TIFF 11394 kb)
Additional file 14: Figure S8. Knockdown of IL-6 in CAF40TKi
fibroblasts inhibits their interaction with MCF10.DCIS cells. (A) CAF40TKi
fibroblasts and MCF10.DCIS cells were transduced with an shRNA
targeting IL-6 mRNA. ELISA quantification of IL-6 secreted from control
(black bars) and IL-6 targeted shRNA cell lines (red bars). (B) MCF10.DCIS
cells co-cultured with CAF40TKi fibroblasts transduced with a scrambled
shRNA virus. (C) Co-culture of MCF10.DCIS cells (unlabeled) with IL-6
shRNA transduced CAF40TKi fibroblasts (green). (D) Co-culture of IL-6
shRNA transduced MCF10.DCIS cells (red) with CAF40TKi fibroblasts
Osuala et al. BMC Cancer  (2015) 15:584 Page 11 of 14
(unlabeled). Scale bars, 200 μm. ***P < 0.001. All statistics are Student’s
t-test; mean ± SD. (TIFF 319 kb)
Additional file 15: Figure S9. IL-6 receptor gene expression and
protein secretion in DCIS cell lines and CAF40TKi fibroblasts. (A)
Examination of IL-6R gene expression. Fold difference as compared to
MCF-10A non-tumor-forming breast epithelial cells. (B) Measurement of
soluble IL-6R in media collected from MAME cultures (determined by
ELISA). **P ≤ 0.001, NS. Not significant, by Student’s t-test; mean ± SD.
(TIFF 119 kb)
Abbreviations
DCIS: Ductal carcinoma in situ; CAFs: Carcinoma-associated fibroblasts;
IL-6: Interleukin 6; IL-6TS: Interleukin 6– trans-signaling; MAME: Mammary
architecture and microenvironment engineering; CFSE: Carboxyfluorescein
diacetate succinimidyl ester; dDQ-col: Degraded dye-quenched collagen;
3D: Three-dimensional; EMT: Epithelial to mesenchymal transition;
ELISA: Enzyme-linked immunosorbent assay; qRT-PCR: Quantative Real-time
polymerase chain reaction; shRNA: Short hairpin ribonucleic acid; LSM: Laser
scanning microscope; DIC: Differential interference contrast; Oxy: Oxymatrine;
DMSO: Dimethyl sulfoxide; DNA: Deoxyribonucleic acid; FDA: Federal Drug
Administration.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KOO and BFS designed research plan; KOO made substantial contributions
to conception, acquisition, analysis and interpretation of data; MS conducted
immunohistochemistry and made substantial contribution to data analysis;
NA, and SS made substantial contributions to data analysis; MLS performed
video editing and contributed to data analysis; KOO, BFS, RRM, SWH, OEF,
YH, and FB drafted the manuscript and participated in revising it for
intellectual content. All authors read and approved the final manuscript.
Acknowledgments
This work was funded in part by a Department of Defense Breast Cancer
Research Program Postdoctoral Fellowship Award (W81XWH-12-1-0024; KO) and
a multi-PI R01 CA131990 from the National Institutes of Health (BFS and RRM).
The Microscopy, Imaging and Cytometry Resources Core is supported, in part,
by NIH Center grant P30 CA022453 to the Karmanos Cancer Institute at Wayne
State University, and the Perinatology Research Branch of the
National Institutes of Child Health and Development at Wayne State University.
Author details
1Department of Pharmacology, Wayne State University, 540 East Canfield,
Detroit, MI 48201, USA. 2Cancer Biology Program, Wayne State University, 540
East Canfield, Detroit, MI 48201, USA. 3Department of Physiology, Wayne
State University, 540 East Canfield, Detroit, MI 48201, USA. 4School of
Medicine, Wayne State University, 540 East Canfield, Detroit, MI 48201, USA.
5Department of Surgery, NorthShore University Health System Research
Institute, 1001 University Place, Evanston, IL 60201, USA. 6Division of Cancer
and Developmental Biology, The University of Kansas Medical Center, 3901
Rainbow Boulevard, Kansas City, KS 66160, USA.
Received: 18 December 2014 Accepted: 27 July 2015
References
1. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of
the breast: a systematic review of incidence, treatment, and outcomes.
J Natl Cancer Inst. 2010;102(3):170–8.
2. Society AC. Cancer Facts & Figures 2014. American Cancer Society.
Cancer.org. 2014;8–10.
3. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of
low-grade ductal carcinoma in situ of the breast in women treated by biopsy
only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481–4.
4. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued
local recurrence of carcinoma 15–25 years after a diagnosis of low
grade ductal carcinoma in situ of the breast treated only by biopsy.
Cancer. 1995;76(7):1197–200.
5. Network NCC. Stage 0 Breast Cancer. NCCN Guidlines for Patients.
2014;1(2014):17–28.
6. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle:
microenvironmental influences in the normal and malignant breast.
Differentiation. 2002;70(9–10):537–46.
7. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models
of normal and malignant breast epithelial cells. Nat Methods.
2007;4(4):359–65.
8. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of
the tumor microenvironment during breast cancer progression. Breast Cancer
Res. 2009;11(1):R7.
9. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, et al. Distinct
epigenetic changes in the stromal cells of breast cancers. Nat Genet.
2005;37(8):899–905.
10. Sung KE, Yang N, Pehlke C, Keely PJ, Eliceiri KW, Friedl A, et al. Transition to
invasion in breast cancer: a microfluidic in vitro model enables examination of
spatial and temporal effects. Integr Biol. 2011;3(4):439–50.
11. Madar S, Goldstein I, Rotter V. Cancer associated fibroblasts’–more than
meets the eye. Trends Mol Med. 2013;19(8):447–53.
12. Campbell I, Polyak K, Haviv I. Clonal mutations in the cancer-associated
fibroblasts: the case against genetic coevolution. Cancer Res. 2009;69(17):6765–8.
discussion 6769.
13. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, et al. No evidence of
clonal somatic genetic alterations in cancer-associated fibroblasts from
human breast and ovarian carcinomas. Nat Genet. 2008;40(5):650–5.
14. Augsten M. Cancer-associated fibroblasts as another polarized cell type of
the tumor microenvironment. Front Oncol. 2014;4:62.
15. Tamm I, Cardinale I, Murphy JS. Decreased adherence of interleukin 6-treated
breast carcinoma cells can lead to separation from neighbors after mitosis. Proc
Natl Acad Sci U S A. 1991;88(10):4414–8.
16. Tamm I, Cardinale I, Kikuchi T, Krueger JG. E-cadherin distribution in
interleukin 6-induced cell-cell separation of ductal breast carcinoma
cells. Proc Natl Acad Sci U S A. 1994;91(10):4338–42.
17. Krueger J, Ray A, Tamm I, Sehgal PB. Expression and function of
interleukin-6 in epithelial cells. J Cell Biochem. 1991;45(4):327–34.
18. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, et al. Twist
is transcriptionally induced by activation of STAT3 and mediates STAT3
oncogenic function. J Biol Chem. 2008;283(21):14665–73.
19. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6
induces an epithelial-mesenchymal transition phenotype in human breast cancer
cells. Oncogene. 2009;28(33):2940–7.
20. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors:
generation and biological function. Biochem J. 1994;300(Pt 2):281–90.
21. Mohamed MM, Cavallo-Medved D, Rudy D, Anbalagan A, Moin K, Sloane
BF. Interleukin-6 increases expression and secretion of cathepsin B by
breast tumor-associated monocytes. Cell Physiol Biochem.
2010;25(2–3):315–24.
22. Bengsch F, Buck A, Gunther SC, Seiz JR, Tacke M, Pfeifer D, et al. Cell
type-dependent pathogenic functions of overexpressed human cathepsin B
in murine breast cancer progression. Oncogene. 2013.
23. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch Jr G, Klocker H, et
al. Immunohistochemical localization of interleukin-6 and its receptor in
benign, premalignant and malignant prostate tissue. J Pathol.
2000;191(3):239–44.
24. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor
proliferative activity in patients with colorectal carcinoma. Cancer.
1999;85(12):2526–31.
25. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in
targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904–10.
26. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J,
Panupinthu N, et al. Growth of triple-negative breast cancer cells relies
upon coordinate autocrine expression of the proinflammatory cytokines
IL-6 and IL-8. Cancer Res. 2013;73(11):3470–80.
27. Jiang XP, Yang DC, Elliott RL, Head JF. Down-regulation of expression of
interleukin-6 and its receptor results in growth inhibition of MCF-7
breast cancer cells. Anticancer Res. 2011;31(9):2899–906.
28. Leslie K, Gao SP, Berishaj M, Podsypanina K, Ho H, Ivashkiv L, et al.
Differential interleukin-6/Stat3 signaling as a function of cellular context
mediates Ras-induced transformation. Breast Cancer Res. 2010;12(5):R80.
Osuala et al. BMC Cancer  (2015) 15:584 Page 12 of 14
29. Lovitt CJ, Shelper TB, Avery VM. Evaluation of chemotherapeutics in a three-
dimensional breast cancer model. J Cancer Res Clin Oncol. 2015;141(5):951–9.
30. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model
for the evolution of cancer from proliferative breast disease. Am J Pathol.
1996;148(1):313–9.
31. Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor
promotes invasion of human mammary ductal carcinoma in situ. Cancer Res.
2009;69(23):9148–55.
32. Sameni M, Anbalagan A, Olive MB, Moin K, Mattingly RR, Sloane BF. MAME
models for 4D live-cell imaging of tumor: microenvironment interactions that
impact malignant progression. J Vis Exp. 2012;(60). doi: 10.3791/3661.
33. Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, Sloane BF. Live-cell
imaging demonstrates extracellular matrix degradation in association with active
cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res.
2009;315(7):1234–46.
34. Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, Ziegler G. Membrane association
of cathepsin B can be induced by transfection of human breast epithelial cells
with c-Ha-ras oncogene. J Cell Sci. 1994;107(Pt 2):373–84.
35. Mullins SR, Sameni M, Blum G, Bogyo M, Sloane BF, Moin K. Three-
dimensional cultures modeling premalignant progression of human breast
epithelial cells: role of cysteine cathepsins. Biol Chem. 2012;393(12):1405–16.
36. Dethlefsen C, Hojfeldt G, Hojman P. The role of intratumoral and systemic
IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657–64.
37. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay
JY. Prognostic value of serum levels of interleukin 6 and of serum
and plasma levels of vascular endothelial growth factor in hormone-
refractory metastatic breast cancer patients. Br J Cancer.
2003;88(11):1721–6.
38. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al.
Circulating interleukin-6 predicts survival in patients with metastatic breast
cancer. Int J Cancer. 2003;103(5):642–6.
39. Yang L, Han S, Sun Y. An IL6-STAT3 loop mediates resistance to PI3K
inhibitors by inducing epithelial-mesenchymal transition and cancer stem
cell expansion in human breast cancer cells. Biochem Biophys Res
Commun. 2014;453(3):582–7.
40. Hung SY, Shih YP, Chen M, Lo SH. Up-regulated cten by FGF2 contributes
to FGF2-mediated cell migration. Mol Carcinog. 2014;53(10):787–92.
41. Patel NA, Patel PS, Vora HH. Role of PRL-3, Snail, Cytokeratin and
Vimentin expression in epithelial mesenchymal transition in breast
carcinoma. Breast Dis. 2014;35(2):113–127.
42. D’Angelo RC, Liu XW, Najy AJ, Jung YS, Won J, Chai KX, et al. TIMP-1 via
TWIST1 induces EMT phenotypes in human breast epithelial cells. Mol
Cancer Res. 2014;12(9):1324–33.
43. Ibrahim SA, Hassan H, Vilardo L, Kumar SK, Kumar AV, Kelsch R, et al.
Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell
properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS
One. 2013;8(12), e85737.
44. Guzman JR, Koo JS, Goldsmith JR, Muhlbauer M, Narula A, Jobin C.
Oxymatrine prevents NF-kappaB nuclear translocation and ameliorates
acute intestinal inflammation. Sci Rep. 2013;3:1629.
45. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin.
Am J Cancer Res. 2011;1(4):482–97.
46. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel
tumor-promoting cell type. Cell Cycle. 2006;5(15):1597–601.
47. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR.
Carcinoma-associated fibroblasts direct tumor progression of initiated
human prostatic epithelium. Cancer Res. 1999;59(19):5002–11.
48. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, et al.
Diversity, topographic differentiation, and positional memory in human
fibroblasts. Proc Natl Acad Sci U S A. 2002;99(20):12877–82.
49. Rowe RG, Keena D, Sabeh F, Willis AL, Weiss SJ. Pulmonary fibroblasts
mobilize the membrane-tethered matrix metalloprotease, MT1-MMP, to
destructively remodel and invade interstitial type I collagen barriers.
Am J Physiol Lung Cell Mol Physiol. 2011;301(5):L683–92.
50. Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL. Intrinsic genetic
characteristics determine tumor-modifying capacity of fibroblasts: matrix
metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion.
Breast Cancer Res. 2007;9(5):R67.
51. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, et al. Molecular
signatures suggest a major role for stromal cells in development of invasive
breast cancer. Breast Cancer Res Treat. 2009;114(1):47–62.
52. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity
and reciprocity. Cell. 2011;147(5):992–1009.
53. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in
cancer progression. Nat Rev Cancer. 2002;2(3):161–74.
54. O’Brien P, O’Connor BF. Seprase: an overview of an important matrix serine
protease. Biochim Biophys Acta. 2008;1784(9):1130–45.
55. Linebaugh BE, Sameni M, Day NA, Sloane BF, Keppler D. Exocytosis of active
cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass.
Eur J Biochem. 1999;264(1):100–9.
56. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, et al.
Collagenase-3 expression in breast myofibroblasts as a molecular marker
of transition of ductal carcinoma in situ lesions to invasive ductal
carcinomas. Cancer Res. 2001;61(19):7091–100.
57. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the
tumor microenvironment. Cell. 2010;141(1):52–67.
58. Peters M, Muller AM, Rose-John S. Interleukin-6 and soluble interleukin-6
receptor: direct stimulation of gp130 and hematopoiesis. Blood.
1998;92(10):3495–504.
59. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk
between paracrine-acting cytokine and chemokine pathways promotes
malignancy in benign human prostatic epithelium. Cancer Res.
2007;67(9):4244–53.
60. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson 2nd RS, et
al. Altered TGF-beta signaling in a subpopulation of human stromal cells
promotes prostatic carcinogenesis. Cancer Res. 2011;71(4):1272–81.
61. Hendrayani SF, Al-Khalaf HH, Aboussekhra A. The Cytokine IL-6 Reactivates
Breast Stromal Fibroblasts through Transcription Factor STAT3-dependent
Up-regulation of the RNA Binding Protein AUF1. J Biol Chem. 2014.
62. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R,
et al. Stromal fibroblasts present in invasive human breast carcinomas
promote tumor growth and angiogenesis through elevated SDF-1/CXCL12
secretion. Cell. 2005;121(3):335–48.
63. Cho YA, Sung MK, Yeon JY, Ro J, Kim J. Prognostic role of interleukin-6,
interleukin-8, and leptin levels according to breast cancer subtype. Cancer
Res Treat. 2013;45(3):210–9.
64. Narita D, Seclaman E, Ursoniu S, Ilina R, Cireap N, Anghel A. Expression of
CCL18 and interleukin-6 in the plasma of breast cancer patients as compared
with benign tumor patients and healthy controls. Rom J Morphol Embryol.
2011;52(4):1261–7.
65. Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum
interleukin-6 and C-reactive protein level in breast cancer patients. World
J Surg Oncol. 2011;9:18.
66. Franco OE, Shaw AK, Strand DW, Hayward SW. Cancer associated fibroblasts
in cancer pathogenesis. Semin Cell Dev Biol. 2010;21(1):33–9.
67. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E,
Mommer C, et al. Tumor-associated macrophages in breast cancer: distinct
subsets, distinct functions. Int J Dev Biol. 2011;55(7–9):861–7.
68. Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor
associated macrophages in tumor stroma as a prognostic marker for breast
cancer patients. BMC Cancer. 2012;12:306.
69. Rudnick JA, Kuperwasser C. Stromal biomarkers in breast cancer
development and progression. Clin Exp Metastasis. 2012;29(7):663–72.
70. Palucka K, Coussens LM, O’Shaughnessy J. Dendritic cells, inflammation, and
breast cancer. Cancer J. 2013;19(6):511–6.
71. Kees T, Egeblad M. Innate immune cells in breast cancer–from villains to
heroes? J Mammary Gland Biol Neoplasia. 2011;16(3):189–203.
72. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G.
Prognostic and predictive impact of intra- and peritumoral immune
infiltrates. Cancer Res. 2011;71(17):5601–5.
73. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune
response: crosstalk between adaptive and innate immune cells during breast
cancer progression. Breast Cancer Res. 2007;9(4):212.
74. Wilson KS, Roberts H, Leek R, Harris AL, Geradts J. Differential gene
expression patterns in HER2/neu-positive and -negative breast cancer cell
lines and tissues. Am J Pathol. 2002;161(4):1171–85.
75. Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG,
et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN
and p53 inactivated triple negative breast cancer model. Oncogene.
2015;34(6):671–80.
76. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington
K, et al. Fibroblast-led collective invasion of carcinoma cells with differing
Osuala et al. BMC Cancer  (2015) 15:584 Page 13 of 14
roles for RhoGTPases in leading and following cells. Nat Cell Biol.
2007;9(12):1392–400.
77. Sung KE, Su X, Berthier E, Pehlke C, Friedl A, Beebe DJ. Understanding the
impact of 2D and 3D fibroblast cultures on in vitro breast cancer models.
PLoS One. 2013;8(10), e76373.
78. To Y, Dohi M, Matsumoto K, Tanaka R, Sato A, Nakagome K, et al. A
two-way interaction between hepatocyte growth factor and interleukin-6 in
tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol.
2002;27(2):220–6.
79. Krishnamurthy S, Warner KA, Dong Z, Imai A, Nor C, Ward BB, et al.
Endothelial interleukin-6 defines the tumorigenic potential of primary
human cancer stem cells. Stem Cells. 2014;32(11):2845–57.
80. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM. Cancer-associated
fibroblasts induce epithelial-mesenchymal transition of breast cancer cells
through paracrine TGF-beta signalling. Br J Cancer. 2014;110(3):724–32.
81. Zhang XL, Topley N, Ito T, Phillips A. Interleukin-6 regulation of transforming
growth factor (TGF)-beta receptor compartmentalization and turnover
enhances TGF-beta1 signaling. J Biol Chem. 2005;280(13):12239–45.
82. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms
and pathologic significances in increase in serum interleukin-6 (IL-6) and
soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody,
tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Blood. 2008;112(10):3959–64.
83. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A,
et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6
monoclonal antibody, in patients with relapsed or refractory multiple
myeloma. Br J Haematol. 2013;161(3):357–66.
84. Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, et al. A phase I/II
study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody,
in metastatic renal cell cancer. Br J Cancer. 2010;103(8):1154–62.
85. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, et
al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan
cytotoxicity in preclinical models of multiple myeloma.
Br J Haematol. 2011;152(5):579–92.
86. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara Jr PN, Van Veldhuizen Jr PJ, et
al. Clinical and correlative results of SWOG S0354: a phase II trial of
CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in
chemotherapy-pretreated patients with castration-resistant prostate cancer.
Clin Cancer Re. 2010;16(11):3028–34.
87. Johnson and Johnson (Janssen Biotech I. SYLVANT™ (siltuximab) Receives
FDA Approval to Treat Multicentric Castleman’s Disease (MCD).
www.jnj.com/news/all/sylvant. 2014.
88. Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, et al. Antitumor
efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse
xenograft models of lung cancer. J Thorac Oncol. 2014;9(7):974–82.
89. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al.
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer
Res. 2011;17(18):6083–96.
90. Axel A, Casneuf T, King P, Alvarez J, Hall B, Sasser K. Abstract 3530: The role
of IL-6 in ER + breast cancer and potential use for Siltuximab, an anti-IL-6
antibody, in ER + breast cancer treatment. Cancer Res. 2013;73(8
Supplement):3530–0.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Osuala et al. BMC Cancer  (2015) 15:584 Page 14 of 14
